The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection

Status unconfirmed · Phase 3

Conditions studied: Cervical Intraepithelial Neoplasia Grade 2/3

In brief

The FRDTM is easy to perform and does not require sophisticated laboratory technology and/or experienced pathologists for test result interpretation. Compared to the Pap smear and HPV test, the FRDTM enables clinicians to obtain test results immediately (within 60 seconds) after the screening. This empowers clinicians in making timely decisions on appropriate patient management, and facilitating patient compliance with follow-up procedures. In addition, the FRDTM requires minimal training and technical support. Due to its advantage of rapid visualization of abnormal cervical lesions (CIN2+) in a cost-effective way, health care professionals can make cervical cancer detection accessible to women worldwide, especially in regions with limited medical resources. This is a cross-sectional study to evaluate the clinical performance of Folate Receptor-Mediated Epithelium Staining (FRDTM) in detecting cervical neoplastic lesions (CIN2+).

Key facts

Study ID
NCT03366493
Run by
GY Highland Biotech LLC
People needed
200
Starts
2017-12-07
Expected to finish
2018-12-07
Last updated by the study team
2017-12-08

Who can join

Age: 20 and older, up to 60. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.